David A. Siegel Avrobio, Inc. Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.15 - $1.48 $35,880 - $46,176	31,200 Added 11.77%	296,300 $379,000
Q4 2023 Feb 14, 2024	BUY	$1.22 - $1.62 $34,770 - $46,170	28,500 Added 12.05%	265,100 $360,000
Q3 2023 Nov 14, 2023	SELL	$0.98 - $1.62 $20,188 - $33,372	-20,600 Reduced 8.01%	236,600 $364,000
Q2 2023 Aug 14, 2023	SELL	$0.58 - $1.31 $43,442 - $98,119	-74,900 Reduced 22.55%	257,200 $244,000
Q1 2023 May 15, 2023	SELL	$0.76 - $1.82 $7,372 - $17,654	-9,700 Reduced 2.84%	332,100 $332,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $0.91 $32,256 - $45,864	-50,400 Reduced 12.85%	341,800 $242,000
Q3 2022 Nov 14, 2022	SELL	$0.68 - $1.11 $119,544 - $195,138	-175,800 Reduced 30.95%	392,200 $252,000
Q2 2022 Aug 15, 2022	SELL	$0.75 - $1.33 $80,850 - $143,374	-107,800 Reduced 15.95%	568,000 $523,000
Q1 2022 May 16, 2022	BUY	$1.29 - $4.04 $337,980 - $1.06 Million	262,000 Added 63.32%	675,800 $892,000
Q4 2021 Feb 14, 2022	BUY	$3.45 - $6.05 $443,325 - $777,425	128,500 Added 45.04%	413,800 $1.59 Million
Q3 2021 Nov 15, 2021	BUY	$5.53 - $9.28 $1.15 Million - $1.93 Million	207,900 Added 268.6%	285,300 $1.59 Million
Q2 2021 Aug 16, 2021	SELL	$7.84 - $12.6 $125,440 - $201,600	-16,000 Reduced 17.13%	77,400 $688,000
Q1 2021 May 17, 2021	BUY	$10.54 - $19.3 $378,385 - $692,870	35,900 Added 62.43%	93,400 $1.19 Million
Q4 2020 Feb 16, 2021	BUY	$12.79 - $17.1 $543,575 - $726,750	42,500 Added 283.33%	57,500 $802,000
Q3 2020 Nov 16, 2020	SELL	$12.99 - $19.41 $11,691 - $17,469	-900 Reduced 5.66%	15,000 $195,000
Q2 2020 Aug 14, 2020	BUY	$12.19 - $22.96 $193,821 - $365,064	15,900 New	15,900 $277,000

Others Institutions Holding AVRO

# of Institutions

Shares Held

559K

Call Options Held

Put Options Held

View Full List

About AVROBIO, Inc.

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

More about AVRO

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account